Secondary Stock OfferingsBy The Online Investor Staff, updated Sat., Sep. 19, 7:09 AM
|This Slide: #21 of 25|
Slide #21. Intra-Cellular Therapies, Inc. — Secondary Offering
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of $350 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intra-Cellular Therapies. -updated 9/10- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 11,666,667 shares of its common stock at a public offering price of $30.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $350 million from the offering of an aggregate of 11,666,667 shares before deducting underwriting discounts and commissions and offering expenses. Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,750,000 shares on the same terms and conditions. The offering is expected to close on September 15, 2020, subject to the satisfaction of customary closing conditions.
Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery and clinical development of small molecule drugs that address medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. Co.'s product candidate, CAPLYTA (lumateperone) has been approved by the United States Food and Drug Administration for the treatment of schizophrenia in adults. Co.'s pipeline also includes preclinical programs that are focused on developing drugs for the treatment of schizophrenia, Parkinson's disease, Alzheimer's disease and other neuropsychiatric and neurodegenerative disorders.
ITCI SEC Filing Email Alerts Service
Open the ITCI Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 90% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite